Since the discovery of induced pluripotent stem cell (iPSC) technology 18 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
iPSCs are Transforming Drug Discovery, Toxicity Testing, Disease Modeling, and Beyond
Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using adult cells. They are derived from somatic cells by reprogramming artificially and turning on the expression of specific pluripotency genes. The reprogramming is achieved using different techniques with varying efficiencies. The iPSC technology was first discovered in 2006 by Shinya Yamanaka’s lab in Kyoto, Japan. He and his team introduced four specific genes encoding transcription factors and converted adult cells into pluripotent stem cells. [Read more…]
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research
Sadly, in July 2025, the California Institute for Regenerative Medicine (CIRM) officially closed its iPSC Repository, marking the end of one of the world’s most comprehensive publicly funded collections of human induced pluripotent stem cell (hiPSC) lines. With the repository’s closure, these cells are no longer available for purchase or distribution, a development that has drawn wide attention and sadness across the global stem cell community. [Read more…]
Qkine launches cell therapy grade recombinant proteins to support next-generation therapies
1st October 2025, Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing. [Read more…]
TEDCO Announces Panel to Discuss the Road to Clinical Trials at 2025 Entrepreneur Expo
COLUMBIA, Md., October 9, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo at The Hotel at the University of Maryland on October 21, 2025.
“The transition from discovery to clinical application represents one of the most complex and pivotal phases of medical research” said Ben Antebi, associate director, Maryland Stem Cell Research Fund (MSCRF). “Navigating this critical pathway properly has a direct impact on shaping the fate of a technology.” [Read more…]
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 339
- Next Page »




